Most patients with advanced non-small cell lung carcinoma (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations will develop resistance after 6–9 months of treatment with first generation reversible tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib[1,2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.